[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371083-105":3,"doc-detail-371083-en":81,"detail-sidebar-cat-0-en-105":99},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tlr9-a-double-dealing-toll-like-receptor","TLR9: A Double-Dealing Toll-Like Receptor","","In 2011, the Nobel Prize highlighted the discovery of Toll-like receptors (TLRs) and their central function in immunity. TLR9 recognizes unmethylated cytosine-phosphate-guanine (CpG) DNA motifs and initiates innate and adaptive immune signaling. Activation engages NF-κB, STAT3, and MAPK pathways to shape inflammation, survival programs, and immune regulation. Despite its importance for defense, TLR9 can function in a “double-dealing” manner across cancer, autoimmunity, and chronic inflammatory disorders, yielding context-dependent, sometimes opposing outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tlr9-a-double-dealing-toll-like-receptor/371083/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tlr9-a-double-dealing-toll-like-receptor/371083.png","ImageObject",300,407,{"name":42,"@type":43},"LangkahRina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does TLR9 detect and how does it trigger immune responses?","Question",{"text":63,"@type":64},"TLR9 detects unmethylated CpG DNA motifs. It activates innate and adaptive immune signaling through pathways that drive transcription factors such as NF-κB, STAT3-related signaling, and MAPK.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is TLR9 described as having “double-dealing” roles?",{"text":68,"@type":64},"TLR9’s effects vary with the pathology and the context of its ligands. The review describes it as both promoting and suppressing disease processes, depending on tumor type, signaling context, and microenvironment.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic approach targets TLR9 in cancer treatment?",{"text":72,"@type":64},"Synthetic CpG oligodeoxynucleotides (ODNs) act as TLR9 agonists and are presented as a promising strategy for cancer immunotherapy, especially when combined with other anticancer therapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371083,1790456802,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",7,"ImmunoTargets and Therapy  \nOpen Access Full Text Article REVIEW  \nTLR9: A Double-Dealing Toll-Like Receptor  \nMegan Nielsen 1 , Daisuke Nishizaki 2 , *, Shumei Kato2 , *, Razelle Kurzrock 1  \n1Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; 2Moores Cancer Center, University of California San Diego, La Jolla, CA, USA  \n*These authors contributed equally to this work  \nCorrespondence: Megan Nielsen, Medical College of Wisconsin, 8701 W Watertown Plank Road, Milwaukee, WI, 53226, USA, [Email mnielsen1@mcw.edu](Email mnielsen1@mcw.edu)  \n\n| Abstract: In 2011, the Nobel Prize was awarded for the discovery of Toll-like receptors (TLRs) and their critical role in immunity. TLR9 is a key pattern recognition receptor that detects unmethylated cytosine-phosphate-guanine (CpG) DNA motifs, triggering innate and adaptive immune responses against pathogens and damaged host cells. Upon activation, TLR9 triggers signaling cascades that drive NF-κB, STAT3, and MAPK pathways, modulating inflammatory responses, cellular survival mechanisms, and immune regulation. While TLR9 activation is essential for immune defense, TLR9 acts as a double-dealing TLR in multiple pathologies, including cancer, autoimmunity, and chronic inflammatory disease. In cancer biology, TLR9 exhibits context-dependent roles, acting as a driver of tumorigenesis, a suppressor of tumor growth, and a regulator of immune responses, depending on the tumor type, signaling pathway, and microenvironment. It promotes tumorigenesis in leukemias, gliomas, and cancers of the prostate, bone, lung, and gastrointestinal tract, yet displays tumor-suppressive effects in triple-negative breast cancer, renal cell carcinoma, and virallyassociated malignancies, through a variety of mechanisms. Clinically, synthetic CpG oligodeoxynucleotides (ODNs), which function as TLR9 agonists, have emerged as a promising approach in cancer immunotherapy, particularly in combination with other potent anticancer therapies. However, the dual nature of TLR9 signaling poses challenges for therapeutic applications. Its context-dependent effects contribute to inconsistent clinical outcomes and raise concerns about safety and toxicity. This review examines the immunologic function and signaling mechanisms of TLR9, with a focus on its complex, context-specific, and “double-dealing” roles in cancer pathogenesis and therapy.\u003Cbr>Keywords: toll-like receptor 9, NF-κB, STAT3, TLR9 agonist, cancer, immunotherapy, inflammation |\n| --- |\n| Introduction\u003Cbr>The 2011 Nobel Prize in Physiology and Medicine was awarded to Bruce Beutler, Jules Hoffmann, and Ralph Steinman for their discoveries regarding immune system function, especially Toll-like receptors (TLRs) .1 The TLR family of pattern recognition receptors (PRRs) identifies pathogen-associated molecular patterns (PAMPs) from invading microbes and damage-associated molecular patterns (DAMPs) from stressed or damaged host cells.2,3 TLRs can be broadly categorized by their cellular localization and ligand types. Cell-surface TLRs (TLR1, TLR2, TLR4, TLR5, TLR6) primarily sense lipid-and protein-based microbial components, whereas endosomal TLRs (TLR3, TLR7/8, TLR9) detect nucleic acids.4 Among the nucleic acid-sensing TLRs, TLR9 is unique in both its ligand specificity and signaling pathways. TLR9 is constitutively expressed in both plasmacytoid dendritic cells (pDCs) and B cells and primarily recognizes unmethylated cytosine-phosphate-guanosine (CpG) DNA–motifs that are common among bacteria and singlestranded DNA viruses, but rare, and usually methylated, in mammalian DNA.5 TLR9 signals through a myeloid differentiation 88 (MyD88)-dependent pathway to activate nuclear factor kappa B (NF-κB), activator protein 1 (AP-1), and a broad interferon regulatory factor (IRF) repertoire—including IRF-1, IRF-5, IRF-7, and IRF-8—stimulating both type I interferons (IFN) and pro-inflammatory cytokines.6 In contrast, TLR3 detects dsRNA and signals exclusively thr","cbCaiboWGsWjxOdc","https://ap.wps.com/l/cbCaiboWGsWjxOdc","pdf",5082413,24,"English","# Introduction\n## Toll-like receptors and nucleic acid sensing\n## Distinct signaling pathways of TLR9\n## Ligand origin and downstream immune outcomes","[{\"question\":\"What does TLR9 detect and how does it trigger immune responses?\",\"answer\":\"TLR9 detects unmethylated CpG DNA motifs. It activates innate and adaptive immune signaling through pathways that drive transcription factors such as NF-κB, STAT3-related signaling, and MAPK.\"},{\"question\":\"Why is TLR9 described as having “double-dealing” roles?\",\"answer\":\"TLR9’s effects vary with the pathology and the context of its ligands. The review describes it as both promoting and suppressing disease processes, depending on tumor type, signaling context, and microenvironment.\"},{\"question\":\"What therapeutic approach targets TLR9 in cancer treatment?\",\"answer\":\"Synthetic CpG oligodeoxynucleotides (ODNs) act as TLR9 agonists and are presented as a promising strategy for cancer immunotherapy, especially when combined with other anticancer therapies.\"}]","TLR9: A Double-Dealing Toll-Like Receptor | PDF",1790191205,60,{"code":4,"msg":82,"data":100},[101,105,109,113,117,122,125,130,135,138,142],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":110,"show_sort_weight":111,"slug":112},"Exam",70,"exam",{"id":114,"doc_module":4,"doc_module_name":25,"category_name":115,"show_sort_weight":98,"slug":116},5,"Comic","comic",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},6,"Technology",50,"technology",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":123,"slug":124},40,"healthcare",{"id":126,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},8,"Research & Report",30,"research-report",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},9,"Religion & Spirituality",20,"religion-spirituality",{"id":133,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":133,"slug":137},"World Cup","world-cup",{"id":139,"doc_module":4,"doc_module_name":25,"category_name":140,"show_sort_weight":139,"slug":141},10,"Lifestyle","lifestyle",{"id":143,"doc_module":4,"doc_module_name":25,"category_name":144,"show_sort_weight":114,"slug":145},19,"General","general"]